Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2017-05-12 Legal Proceedings Report
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
CPEng
Legal Proceedings Report Classification · 1% confidence The document is a press release dated May 12, 2017, detailing an action taken by the French regulatory body (ANSM) regarding the temporary suspension of clinical studies due to Good Clinical Practice (GCP) deviations. It discusses the company's response, corrective actions, audit plans, and the impact on ongoing studies (like the ALS study). This content focuses on regulatory compliance, clinical trial management, and data integrity issues related to drug development, which falls under the scope of significant operational and legal disclosures. Since it is a press release announcing a regulatory/legal development concerning clinical trials and compliance, it is best classified as a Legal Proceedings Report (LTR) or potentially a Regulatory Filing (RNS) if LTR is too specific. Given the focus on regulatory findings (ANSM request, GCP deviations, audit plan), LTR is the most precise fit among the specific options, as it relates to regulatory action impacting operations, similar to a lawsuit update. It is not a standard financial report (10-K, IR, ER) or a management/board change announcement.
2017-05-12 English
CPFR
Legal Proceedings Report Classification · 1% confidence The document is a press release from AB Science dated May 12, 2017, detailing a regulatory action by the ANSM (French National Agency for the Safety of Medicines) to temporarily suspend clinical studies in France due to Good Clinical Practice (GCP) deviations. It discusses the company's corrective actions, the planned independent audit, and the impact on ongoing trials (like those for masitinib). This type of announcement, which communicates significant legal, regulatory, or operational developments that impact the company's core business (drug development) but is not a standard periodic financial report (like 10-K or IR), best fits the category for Legal Proceedings Report (LTR) or potentially Regulatory Filings (RNS). Given the focus is specifically on regulatory findings, inspection results, and subsequent actions/disputes with a health authority (ANSM), LTR is highly relevant. However, since it is a general announcement about a regulatory finding and subsequent corrective plan, and not solely focused on a lawsuit, RNS (Regulatory Filings - the general fallback for non-standard regulatory news) is also a strong candidate. Since the content is a direct communication about regulatory compliance issues and findings from an inspection, which often falls under legal/regulatory disclosures, LTR is chosen as it specifically addresses issues with regulatory bodies impacting operations. If LTR were not available, RNS would be the fallback. The document is not a standard financial report, earnings release, or management discussion.
2017-05-12 French
Rapport financier annuel 2016
Annual Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER ANNUEL DU GROUPE AB SCIENCE AU 31 DECEMBRE 2016' (Annual Financial Report). It contains a comprehensive management report, consolidated financial statements, and audit reports for the full fiscal year 2016. This aligns perfectly with the definition of an Annual Report (10-K equivalent for non-US entities). FY 2016
2017-05-01 French
CPEng
Earnings Release Classification · 1% confidence The document is an earnings release from AB Science SA. It provides a summary of 2016 financial results, key clinical trial events, and capital financing updates. While it mentions that the full audited financial report is available on the company's website, the document itself provides the key highlights and financial performance metrics for the period, fitting the definition of an Earnings Release (ER). FY 2016
2017-05-01 English
CPFR
Earnings Release Classification · 1% confidence The document explicitly states it announces 'ses résultats financiers annuels arrêtés au 31 décembre 2016' (its annual financial results established as of December 31, 2016). It details key events from 2016 and recent events since year-end, which is characteristic of an annual financial report summary. Although it mentions the audited report is available, the content provided is a comprehensive summary of financial performance, clinical trial updates, and financing activities for the full year. This aligns best with the content expected in an Annual Report (10-K) or a detailed Annual Results announcement, which in this context is best classified as 10-K given the comprehensive nature and annual scope, even if it's a press release version rather than the full SEC filing. FY 2016
2017-05-01 French
CPFR
Capital/Financing Update Classification · 1% confidence The document is explicitly titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces that AB Science has successfully completed a 'placement privé' (private placement) of new ordinary shares, raising EUR 19.00 million. This action involves raising capital through the issuance of new shares to qualified investors. This directly corresponds to the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and capital structure changes. It is not an Earnings Release (ER), Interim Report (IR), or a full Annual Report (10-K). The document details the terms of the capital increase (price, number of shares, dilution) and the use of proceeds, confirming it is a primary announcement about financing activity.
2017-03-31 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.